APBCS Speakers

NA

Dr Alistair Ring is a Consultant Medical Oncologist at The Royal Marsden. He undertook his pre-clinical training at the University of Cambridge and clinical training at the University of Oxford, qualifying in 1997. His oncology training was based at The Royal Marsden, St George’s and Guy’s Hospitals, London. He gained his MD research degree in 2005 from the Institute of Cancer Research (ICR) at the University of London. In 2008 he was appointed as Senior Lecturer in Oncology at Brighton and Sussex Medical School, where he held various roles including Director of the Brighton NIHR Clinical Research Facility. In 2014 he was appointed Consultant Medical Oncologist at The Royal Marsden. He has specialist interests in the management of metastatic and early breast cancer and the management of cancer in older patients. He has a major interest in research and is UK lead for a number of research studies examining the roles of aspirin and modern targeted drugs in the management of breast cancer. He is Chair of the Committee for Clinical Research at The Royal Marsden and the ICR. Dr Ring has published widely in peer-reviewed journals and in 2015, edited the textbook Problem Solving in Older Cancer Patients and in 2017 Breast Cancer Survivorship. He is a previous chair of the NCRI Advanced Breast Cancer subgroup, which oversees trials for advanced breast cancer in the UK. He is a member of the American Society of Clinical Oncology. In 2018 Dr Ring was appointed Honorary Reader in Breast Cancer Clinical Trials, at the Institute of Cancer Research.

Professor Ava Kwong is Daniel C K Yu Professor in Breast Cancer Research and Clinical Professor at The University of Hong Kong, Chief of Division of Breast Surgery at Queen Mary Hospital, Tung Wah Hospital and The University of Hong Kong-Shenzhen Hospital. In 2007, she founded and is Chairman of the Hong Kong Hereditary Breast Cancer Family Registry. In 2012, she was appointed as the co-leader of the Cancer Work Group in the development of Cancer Services planning of the Hong Kong West Cluster. In 2013, she was elected to be the Deputy Chief and Committee Member of the Shenzhen Breast and Endocrine Cancer Society, China. She has been appointed to be a member of the Cancer Coordinating Committee of the Food and Health Bureau, the Government of the HKSAR since 2014. She is also currently a member of several committees including Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR) and Central Committee on Cancer Service of Hospital Authority, Expert Advisory Panel (Cancer) of Health and Medical Research Fund (HMRF) of Food and Health Bureau, the Government of the HKSAR. Professor Kwong’s research interests focus on breast and ovarian cancer genetics, advanced surgical technologies, epidemiology, psychosocial and clinical trials in oncological treatment. She has received grant support from the Government of the HKSAR including a commissioned grant to study the risk factors of breast cancer in 2015 and various HHSRF grants, Innovation and Technology Fund, Research Grant Council and National Institute of Health in the USA. In 2018, she was awarded a RMB 12 million San Ming Project of Medicine Grant from the Health and Family Planning Commission of Shenzhen Municipality, Government of Shenzhen, China. She has gained multiple awards in various local and international meetings including the “Uccio Querci della Rovere Award” of The Royal College of Surgeons of England in 2019, “Young Investigator Awards” of Hong Kong international Cancer Congress in 2006 and 2008. She has authored chapters in local and international textbooks including ‘Psycho-oncology, 4th edition’, ‘ABC of Breast Disease’, ‘Companion to Specialist Surgical Practice: Breast Surgery’, ‘Up To Date’ on-line medical website. She also has over 160 peer reviewed publications in reputable international journals. She also founded and was elected chairlady of the Women’s Surgical Chapter, College of Surgeons of Hong Kong and elected the Chair of the International Committee of the Association of Women Surgeons, USA. In 2011, she became the first woman council member of the College of Surgeons of Hong Kong and is the first female Clinical Professor in Surgery in Hong Kong.

Dr. Muhammad Azrif graduated from the Royal Free Hospital & University College London School of Medicine, London, UK in 1997. After completing his training in internal medicine and obtaining his MRCP (UK) in 2000, he entered the specialist training programme in Clinical Oncology at the Christie Hospital, Manchester, UK. He became a Fellow of the Royal College of Radiologists (Clinical Oncology) in 2005 and attained his Certificate of Completion of Specialist Training (UK) before admission to the UK General Medical Council Specialist Register in 2006. He was awarded a one-year Clinical Research Fellowship to the Department of Radiation Oncology, University of Toronto, Canada in mid-2006. He returned to Malaysia in 2007 and served at the National University of Malaysia Medical Centre (UKMMC) as a Consultant Clinical Oncologist for 5 years before joining private practice in 2012. He has served on various national oncology committees, published in peer-reviewed journals as well as participated in numerous clinical trials, cancer advisory boards, and expert panels.

Associate Professor Benita Tan is the chief of Breast Service and Senior Consultant in the Department of General Surgery in Sengkang General Hospital, and the current Chairman of the Division of Ambulatory and Outpatient Services at Sengkang General Hospital. A/Prof Tan is also a Senior Consultant at the Department of Breast Surgery, Singapore General Hospital and Division of Surgical Oncology in National Cancer Centre, Singapore. A/Prof Benita holds concurrent appointments of Associate Professor in the Yong Loo Lin School of Medicine, NUS, and Associate Professor with the Duke-NUS Medical School. She is currently serving various administrative positions in SingHealth and Sengkang General Hospital such as Member of the Academic Medicine Council for Surgery ACP, Office of Academic & Clinical Development, Academic Development Department, Duke-NUS and various others. A/Prof Tan graduated with a Bachelor of Medicine and Surgery in the National University of Singapore in 1995. She trained as a general surgeon, completed her Membership examination of the Royal College of Surgeons of Edinburgh in 1999 and obtained Master of Medicine (Surgery), National University of Singapore a year after in 2000. She continued to pursue the advanced specialty training in General Surgery and was accredited as a specialist in General surgery in 2003, with the Fellowship Examinations of the Royal College of Surgeons of Edinburgh (General Surgery), before sub-specializing in breast surgery in particular breast cancer surgery. She attained her Doctor of Philosophy, at Saw Swee Hock School of Public Health, National University of Singapore in 2013. A/Prof Tan sees, manage, and provide treatment recommendations and surgical expertise for a range of breast diseases, both benign and malignant. Experienced in a wide range of breast procedures, she performs breast biopsies including vacuum assisted biopsies (VAB) and breast cancer surgeries, from breast conserving cancer surgery to mastectomies including skin-sparing, nipple sparing and endoscopic mastectomy for breast reconstruction. She works with a multi-disciplinary team including medical oncologists, radiation oncologists, pathologists, radiologists, breast cancer nurses, occupational therapists to provide our breast cancer patients a holistic and individualised care plan that they deserve. Besides clinical excellence, A/Prof Tan enjoys teaching and shares her clinical experiences with students from the Yong Loo Lin, School of Medicine, Duke NUS Graduate Medical School, residents from the General Surgery and Family Medicine programmes as well as trainees in the Resident Nursing programme. She is also involved in a wide range of breast cancer research both clinical and translational locally and internationally, and has numerous publications in peer reviewed international journals.

Dr Brendan Pang obtained the FRCPath (UK) and qualified as a histopathologist. He then trained in the Diagnostic Molecular Oncology Centre (DMOC), a College of American Pathologists (CAP) accredited molecular diagnostic laboratory under the mentorship of Professor Manuel Salto-Tellez. He furthered his training in molecular pathology as a visiting scholar at the University of Pittsburgh Medical Centre’s (UPMC) Molecular Anatomic Pathology (MAP) laboratory, Presbyterian Hospital, under Dr Marina Nikiforova, chair-elect of the solid tumours sub-division of the Association of Molecular pathology (AMP) and returned to Singapore as the Director of DMOC. He was appointed as an honorary pathology fellow at the Cancer Science Institute (CSI) in 2012 and has had research collaborations with the Genome Institute of Singapore (GIS) and other PIs from the Yong Loo Lin School of Medicine. His research interests lie in the development of novel biomarker assays using molecular platforms.

Chiun-Sheng Huang is the Chairman and Professor of Department of Surgery at the National Taiwan University Hospital and National Taiwan University College of Medicine. He is also the director of Breast Care Center at the National Taiwan University Hospital, Taipei, Taiwan. He is currently the chairman of Taiwan Breast Cancer Consortium, an academic research organization focusing on multi-center clinical trials.

Dejan Juric is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Juric is highly rated in 17 conditions and his top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. He is board certified in Medical Oncology and Internal Medicine and licensed to treat patients in Massachusetts.

Dr Elaine Lim is Senior Consultant, Division of Medical Oncology, National Cancer Centre of Singapore (NCCS); Director, Division of Community Outreach & Philanthropy, NCCS; President, Singapore Society of Oncology; Senior Clinician Scientist, Genome Institute of Singapore; Clinician Researcher, Institute of Molecular & Cell Biology, Singapore. After graduating from Trinity College, University of Cambridge, Dr. Lim was selected to join the Cambridge MBBCh-PhD programme. Her PhD dissertation on molecular genetics was supervised by Nobel Laureate, Professor Sydney Brenner and Professor Timothy Cox. After completing her clinical training in Cambridge, Dr. Lim worked in London, which included the Royal London Hospital and the prestigious London ‘golden circuit’ of Hammersmith Hospital and Royal Brompton Hospital. Upon her return to Singapore, she joined the National University of Singapore (NUS) and National University Hospital (NUH) to pursue a career in Medical Oncology. She later moved to Johns Hopkins Singapore as Consultant in Medical Oncology, as well as being Visiting Consultant at Tan Tock Seng Hospital (TTSH) and Kandang Kerbau Women’s and Children’s Hospital (KKH). After a few years in private practice with Singapore Oncology Consultants, she joined the National Cancer Centre of Singapore. She has continued her laboratory research activities in collaboration with the Genome Institute of Singapore and the Institute of Molecular and Cell Biology, and actively participates in clinical trials. She founded Breast Cancer Research Singapore, a consortium of clinicians and scientists dedicated to basic and translational breast cancer research in Singapore, whose Patron is the President of Singapore, Her Excellency Halimah Yacob. Dr. Lim spearheaded NCCS Home Care, and has contributed to national healthcare financing and policy workgroups set up under the auspices of the Ministry of Health, Singapore.

Dr. Ellie May Villegas was Past President of the Philippine Society of Medical Oncology and Chair of the Philippine Specialty Board of Medical Oncology. Presently, she is Co-chair of the Perpetual Succour Hospital Institutional Ethics and Review Board and is the Section Head of the Hematology-Oncology Unit of the Perpetual Succour Hospital, Cebu Cancer Institute. Our distinguished speaker is also an Associate Professor at the Cebu Doctors’ University Hospital and is an active member of the medical staff of various hospitals including Chong Hua Hospital, Visayas Community Medical Center, and Cebu Velez General Hospital. She is a principal investigator and co-investigator to over 21 major clinical trials, both on-going and in-press.

Dr Faye was born and raised in East Malaysia and graduated from University in Nottingham, UK. She has worked in several hospitals in Queensland since 2015 including Nambour, Redlands, Princess Alexandra and the Bundaberg Hospital, and in various disciplines including Emergency Medicine, Obstetrics and Gynaecology, and various Internal Medicine sub-specialties. Faye has an interest interested in all aspects of General Practice for now and looks forward to starting at the Family Health Clinic soon. In her free time she likes to read, draw, workout, and play the guitar. ​She also speaks basic Mandarin and Malay.

Dr. Burstein graduated from Harvard College before earning his MD at Harvard Medical School. He also received a PhD in cellular immunology and a master's degree in the history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital before his oncology fellowship at DFCI. In 1999, he joined the staff of DFCI and Brigham and Women's Hospital, where he is a clinician and clinical investigator in the Breast Oncology Center.

Hiroji Iwata is an Oncologist and a General Surgeon in Nagoya, Japan. Iwata is rated as an Advanced expert by MediFind in the treatment of Paronychia. They are also highly rated in 12 other conditions, according to our data. Their top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Peripheral Neuropathy, and Triple-Negative Breast Cancer. Their clinical research consists of co-authoring 342 peer reviewed articles and participating in 1 clinical trial in the past 15 years. In particular, they have co-authored 2 articles in the study of Paronychia.

Dr Jack Chan is a Consultant Medical Oncologist. His subspecialty interests are gynaecological cancers and breast cancer. His research interests include early and late phase clinical trials and translational work in these cancers. He is the Principal Investigator of investigator-initiated and industry-sponsored trials at National Cancer Centre Singapore. Dr Chan is also active in teaching Senior Residents, medical officers, medical and nursing students; as well as in professional societies such as Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He has received accolades for his education and clinical work, including Residency in SingHealth Excels Outstanding Faculty Award 2020 and Singapore Health Quality Service Awards (Silver 2019, Gold 2020).

Janice Tsang is a Specialist in Medical Oncology and the Honorary Clinical Assistant Professor at the Li Ka Shing Faculty of Medicine, HKU, and Founding Convenor of HKBOG, Hong Kong. Dr Tsang’s research interests lie mainly in breast oncology, geriatric oncology, translational research and psycho-oncology. Being the first female academic medical oncologist at The University of Hong Kong (HKU), she was awarded the 2014 Hong Kong Ten Outstanding Young Persons Award, and the 2012 Hong Kong City Lady Award (Professional & Academic Category) as the only medical professional receiving this award for the year. She was also the winner of the Psychosocial Oncology Young Investigator Award at the 16th Hong Kong International Cancer Congress & 6th Annual Meeting of Centre for Cancer Research in 2009, and was bestowed the Faculty Teaching Medal in 2012, and the Outstanding Teaching Award (Team Award) for Medical Humanities in 2013 in recognition of her being one of the pioneers in incorporating medical humanities in the formal medical curriculum. She has conducted over 80 clinical trials, including local, regional and international multicenter clinical trials. She has been serving as Chairperson for the Data Monitoring Committee, Steering Committee members for major multi-centered clinical trials, as well as various international and regional advisory boards. She is a key opinion leader in breast oncology both locally and regionally. She is also the Founding Convenor of the HKBOG, which is now a member of the ‘Breast International Group’, being the 3rd Asian member after Japan and Taiwan. She is also appointed as Chair of the CTRG Audit Committee for the National Cancer Institute in 2017, and a member of the International Society of Geriatric Oncology (SIOG), serving as co-track chair for translational research in SIOG. She is also the Co-Chair of the Organizing Committee of the 8th Global Chinese Breast Cancer Organizations Alliance Conference 2021. Dr Tsang is currently member of the Specialty Board of Medical Oncology and used to be the Programme Director for Medical Oncology in the Hong Kong Island at the Hong Kong College of Physicians; a member of the Coordinating Committee (CoC) for Medical Oncology at the Hospital Authority; Deputy Chairperson for the Institutional Review Board for the Hong Kong West Cluster/HKU; and Director of Cancer Centre at Queen Mary Hospital, Hong Kong. She has various appointments in different professional bodies, such as Honorary Advisor for various cancer self-help groups, including the Hong Kong Christian Cancer Care Association and the Hong Kong Cancer Fund. Furthermore, she serves as member of the Social Welfare Advisory Committee and the Rehabilitation Advisory Committee in Hong Kong. She also serves as Deputy Chairman for the Women for Oncology Committee at the European Society of Medical Oncology (ESMO) for the term of 2020–2021, and as Founding Convenor of the Hong Kong Women for Oncology (HKW4O).

Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996, specialist in Medical Oncology by the Clínica Universitaria de Navarra, and awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d'Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology. In addition he was the Head of the Breast Cancer Program from July 2006 to August 2015. From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. Dr. Cortes was the Head of the Breast Cancer Program at IOB Institute of Oncology, Quironsalud group, in both Madrid and Barcelona, from 2011 to September 2020. Actually, Dr. Cortés is the Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials, and Senior Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology. In addition to his medical specialties, he has two master degrees in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona. He is the author of more than 330 publications, especially about breast tumours and new drugs and more than 800 communications at different conferences. He actively participates in the development of numerous international clinical trials, and he is an ad hoc reviewer of various oncology journals, including, New England Journal of Medicine, Lancet, Lancet Oncology, Annals of Oncology or Journal of Clinical Oncology, among many others Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO). In addition, he is a member of the Scientific Committee of the European Society of Medical Oncology (ESMO), Chair of the Committee for Breast Cancer, local therapy, ESMO 2020 and Co-Chair of the American Association for Cancer research (AACR) Annual Meeting 2021 Program Committee.

Dr Joline Lim is Consultant at the Department of Haematology-Oncology at the National University Cancer Institute, Singapore – NCIS (part of NUHS). Joline’s study on “Combination and triplet therapy for breast cancer patients” was an early phase clinical trial investigating a novel combination of targeted cancer treatments to understand its effect on patients with advanced refractory cancers. The study successfully showed that this combination had the potential to improve patient outcomes, especially in breast cancer patients for which hormonal therapy is no longer effective.

Dr Karmen Wong is a medical oncologist with more than 30 years of clinical practice. She received her oncology training at the National University Hospital (NUH), National Cancer Centre, Singapore (NCC) and University of California, San Francisco (UCSF), who have a reputation for health sciences research and patient care under the HMDP scholarship. She helped establish the first multi-disciplinary breast cancer treatment in Singapore 20 years ago in NCC, which created a platform for treatment in other cancer types with doctors of different disciplines. Dr Wong also initiated the bone marrow transplant programme in solid tumour in Singapore General Hospital (SGH) in 1997. She also won an award for her oral presentation at the 9th Annual Scientific Meeting in SGH in 1988. She is also currently running a strong cancer support network in her practice. In addition, she is also a co-investigator in various clinical trials on new cancer treatments. These include the CompLEEment-1 trial study that were presented in ASCO 2019 (American Society of Medical Oncology) and ESMO 2018 (European Society for Medical Oncology) meetings. Dr Wong presented the 1st Asian study in attitudes towards breast cancer treatment among Asian patients in the Annual Meeting of the American Society of Clinical Oncology in 1999. She has also written numerous peer review articles and published chapters in textbooks. She also gives lectures in the ASEAN regions on cancer treatment updates. Dr Karmen Wong accepts referrals for all cancer types, with a special clinical interest in breast, gastrointestinal and gynaecological cancers.

Dr Khoo Kei Siong is a Deputy Medical Director and Senior Consultant, Medical Oncologist at Parkway Cancer Centre. His subspecialty interests are in breast cancer and gynaecological cancer. Dr Khoo Kei Siong graduated from the National University of Singapore and received his training in Internal Medicine and Medical Oncology at the Singapore General Hospital. He was awarded the Singapore Government HMDP fellowship in 1993 to pursue advanced training and research in breast cancer at the Memorial Sloan Kettering Cancer Centre in New York. Before Dr Khoo Kei Siong moved to his current practice, he was a Senior Consultant and Head of Department of Medical Oncology at the National Cancer Centre (NCC). He was the founding Director of the Division of Clinical Trials and Epidemiological Sciences. Dr Khoo Kei Siong is a member of the American Society of Clinical Oncology, the European Society of Medical Oncology and a fellow of the Royal College of Physician in Edinburgh. He was President of the Singapore Society of Oncology from 1998 to 2000. He also served as the Assistant Master – Administrative Affairs in the Council of the Academy of Medicine, Singapore from 2015 to 2020. Dr Khoo Kei Siong presently sits on the Medicine Advisory Committee in the Health Sciences Authority as its Deputy Chairman. He has been actively involved in clinical trials since 1992, and has been Principal Investigator for more than 10 clinical trials. He is currently involved in the ongoing studies on Trastuzumab, HER2 positive breast cancer and CDK 4/6 inhibitors in hormone sensitive breast cancer.

Kiley Loh Dr Kiley Loh Wei-Jen graduated from the University of Melbourne, Australia in 2005. After stints at several tertiary healthcare centres in Melbourne for his basic physician training, he successfully entered the Victorian Medical Oncology Training Group programme to undertake subspecialty training in medical oncology. His medical oncology training included stints at Melbourne based hospitals; Alfred Hospital, Cabrini Hospital and the highly regarded Peter MacCallum Cancer Centre.

Dr. Komal Jhaveri is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. She received her medical degree from KJ Somaiya Medical College and has been in practice 16 years. Dr. Jhaveri accepts several types of health insurance, listed below. She is one of 416 doctors at Memorial Sloan-Kettering Cancer Center who specializes in Oncology. She also speaks multiple languages, including Gujarati, Hindi, Marathi, and Urdu.

Dr Lee obtained her medical degrees from the National University of Singapore and the Royal College of Physicians, United Kingdom, and completed a fellowship in cancer genetics at Johns Hopkins School of Medicine, United States. She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specializes in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumors and haematological malignancies at the National University Cancer Institute.

Dr Mabel Wong is a Senior Consultant in the Division of Medical Oncology at National Cancer Centre Singapore, and Visiting Consultant at Changi General Hospital. She obtained her undergraduate medical degree from the National University of Singapore. Dr. Mabel has been practising in Singapore since 2008, focusing mainly on medical oncology. Her research interests include early phase clinical trials in breast and gynaecology oncology and neo-adjuvant therapy in breast cancer. She is part of the core faculty for Senior Residency Program (Medical Oncology) in curriculum planning and a clinical tutor at the Yong Loo Lin School of Medicine, Singapore. Her other appointments include being the Chairperson, Chemotherapy Safety Committee at the National Cancer Centre aside from her role as an educator.

Massimo Cristofanilli, MD, is an accomplished board-certified medical oncologist with more than two decades of experience as physician, investigator, researcher and leader. He has demonstrated original and innovative vision in the field of molecular diagnostics, liquid biopsy, translational research and drug development. Additionally, Dr. Cristofanilli has an extensive background in clinical trial design and is a key thought leader in the field of metastatic and locally advanced breast cancer.At Weill Cornell Medicine and NewYork-Presbyterian, Dr. Cristofanilli serves as the Director of Breast Medical Oncology, the Associate Director of Precision Oncology at the Meyer Cancer Center (MCC), and the co-leader of the MCC Breast Cancer Disease Management Team, as well as the Scientific Director of the Englander Institute of Precision Medicine (EIPM).Dr. Cristofanilli received his medical degree from the University “La Sapienza” in Rome with Honors where he subsequently completed his fellowship in medical oncology. He completed an Internal Medicine residency at Cabrini Medical Center in New York and a medical oncology fellowship at The University of Texas MD Anderson Cancer Center, where he also served as Faculty in the Department of Breast Medical Oncology for more than a decade.Dr. Cristofanilli has held several leadership positions over the years, including Chairman of Medical Oncology and Associate Director of Clinical Research at the Fox Chase Cancer Center and Associate Director of Translational Research at Thomas Jefferson University. From 2015-2021, Dr. Cristofanilli was Professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago where he also served as the Director of the Breast Disease Team, Director of the Robert Lurie Cancer Center OncoSET Precision Medicine Program, and Associate Director of Clinical Research.In addition to his clinical expertise, Dr. Cristofanilli’s research focuses on biomarkers of endocrine resistance in breast cancer, liquid biopsies and novel drug development. His research in the areas of novel drug development, circulating tumor cells (CTCs) and ctDNA have led to improved treatments for breast cancer. Dr. Cristofanilli is an internationally recognized expert in the research and treatment of Inflammatory Breast Cancer (IBC), the most aggressive and deadly form of breast cancer. He is the founder and President of the IBC International Consortium (IBC-IC). Additionally, Dr. Cristofanilli is globally recognized for his contributions on the detection of micrometastatic disease in breast cancer and a key opinion leader in drug development in hormone-receptor positive metastatic breast cancer. He has co-authored more than 400 peer-reviewed manuscripts.

Dr. Mastura Md Yusof's area of expertise in clinical oncology encompasses radiation therapy, medical oncology and cancer palliation as well as clinical research in breast, colorectal and gastrointestinal cancers and various cancer sites. For her outstanding work and efforts, Dr Mastura was awarded the Universiti Malaya Excellent award for 2014. Dr Mastura serves as consultant in various advisory boards and expert committee panels for cancer and cancer-related services in government such as good oncology practice and chemotherapy protocol guideline, as well as in private sectors. Dr Mastura is currently an EXCO member of the Malaysian Oncological Society and a member of the Academy of Medicine Malaysia (AM), European Society of Medical Oncology, American Society of Clinical Oncology and European Society for Therapeutic Radiology and Oncology. She has worked and shared her expertise with NGOs championing cancer awareness, early diagnosis and treatment within Malaysia and South East Asia.

A/Prof Mikael Hartman has been practising in Singapore since 2009 and is originally from Stockholm, Sweden where he received his training at Karolinska Institute. That is also where he received his board certification in General Surgery in 2005. Having completed his doctoral studies in the field of epidemiology in 2007, he specializes in the field of breast cancer etiology and prognostification as well as inheritance of cancer prognosis. He has been a co-recipient of the Breast Cancer Concept Award, US Army, in 2002 and 2006. He heads a research group of more than ten members including three PhD students and is leading the development of the Singapore Breast Cancer Cohort and the Singapore-Malaysia Breast Cancer Working Group and the Breast Cancer Prevention Programme in the Saw Swee Hock School of Public Health (SSHSPH). The research has been published in Lancet Oncology, Journal of Clinical Oncology, Breast Cancer Research, British Journal of Surgery, European Journal of Cancer etc. He serves as the Deputy Director of the Initiative for Research and Innovation in Surgery – NUHS, the Research Director of the University Surgical Cluster Research Committee – NUHS, the Head of Surgical Clinical Epidemiology Unit - NUHS, Deputy Head of Breast Services in Department of Surgery – NUH and a member of SSHSPH Senior Management Committee and Faculty Promotion and Tenure Committee.

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005-2009, she was an assistant professor and head of Conservative Senology at TUM and from 2009-2011, she was head of the Breast Center at the University of Cologne, Germany. Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). She is scientific director of the West German Study Group (www.wsg-online.com). From 2009-2015, she served on the executive board of the EORTC as the chair of the translational research division. Professor Harbeck is principal investigator or steering committee member of numerous breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com). Professor Harbeck has authored more than 480 papers in peer-reviewed journals (h-index 82) and is coordinating editor-in-chief of Breast Care (Karger Publishers). She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St Gallen). In 2020, Professor Harbeck received the 2020 ESMO Lifetime Achievement Award. She has also numerous other recognitions of her clinical and translational research such as the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract.

Dr. Nitesh Rohatgi is Senior Director Medical Oncology at Fortis Memorial Research Institute, Gurugram, he was previously working at the prestigious London Oncology Clinic (Leaders in Oncology care), Harley Street, London. He is a fellow of the Royal College of Physicians (U.K Edinburgh) as well as Royal Society of medicine. Besides being a key opinion leader in Oncology in India he has been a PI on clinical trials ( presently for BIRAC -Oncology ) and has much publication to his name. He was trained in medical oncology, palliative medicine and teenage young adult’s cancers in United Kingdom, completing his CCT in 2009. Specialty Interests Breast Cancer Lung cancer Gynecological Cancer Gastrointestinal and Hepatobiliary cancers Brain Tumors Head and Neck Cancers Kidney Bladder and Prostate Cancers

Dr Nur Fadhlina is a consultant in clinical oncologist and lecturer at University Malaya Medical Centre, Kuala Lumpur. She graduated from University of Nottingham Medical School in 2006, and completed her MRCP in 2009. She was trained at University College London Hospital and Barts NHS Trust, and subsequently obtained FRCR and Masters in Clinical Oncology under Institute Cancer Research. She attained Certificate for Completion of Specialist Training (CCST) in 2017 from GMC (UK). Her interest in medical education has generated publication in Clinical Oncology journal, and web based learning tool on Royal College Radiologists' (UK) website. Her clinical areas of interests are head and neck, thyroid, breast and gastrointestinal cancers. She is passionate on issues pertaining to medical education, value-based medicine, improving access to cancer care and cancer survivorship. She actively collaborates with researchers locally and internationally in clinical trials. Her research interests encompass targeted therapies in cancer therapeutics as well as digital health intervention in improving cancer care delivery. She heads Cancer ECHO project UM with the aim of improving access to cancer education throughout Malaysia.

Philippe Bedard, MD, is an Associate Professor of Medicine at the University of Toronto. He is a Staff Medical Oncologist in the Division of Medical Oncology and a Principal Investigator in the Bras Drug Development Program at the Princess Margaret Cancer Centre. He is the co-contact Principal Investigator for the North American Star Consortium (NASC), a US National Cancer Institute (NCI) Experimental Therapeutics Clinical Trials Network (ETCTN) UM1-funded consortium that conducts early phase investigator-initiated clinical trials with new therapies for solid tumors and hematologic malignancies. He received the 2017 William E. Rawls Prize from the Canadian Cancer Society, given to a young investigator whose outstanding contributions have the potential to lead to, or have already led to important advances in cancer control. He is the Past Chair for the Canadian Clinical Trials Group (CCTG) Investigational New Drug (IND) Committee and the Clinical Director for the Cancer Genomics Program at the Princess Margaret Cancer Centre. He is Chair of the American Association for Cancer Research (AACR) Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE), an international clinical and genomic data-sharing initiative. His clinical practice includes the treatment of patients with breast and testicular cancers. His research involves early phase clinical trials with novel cancer drug treatments including immunotherapy agents and the personalization of cancer treatment based upon the results of testing for DNA mutations within tumor cells.

Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials.

Rina Hui is a Clinical Professor at the University of Sydney and a Senior Medical Oncologist at the Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia. After completing her medical degree at The University of Sydney and specialist training at The Royal North Shore Hospital, Rina undertook translational research in molecular biology of breast cancer at the Garvan Institute of Medical Research and was awarded a PhD degree. Her major clinical interests are lung cancer and breast cancer management. She currently serves as Co-Chair of Oncology Block at the University of Sydney. She is the Head of Clinical Trials at the Westmead Breast Cancer Institute, a member of the clinical advisory board and research advisory committee of the Westmead Breast Cancer Institute, a member of the Medical Oncology Group of Australia Expert Group for lung cancer, a member of the Breast Cancer Trials and the Australasian Lung Cancer Trials Group. She was a member of the Immuno-Oncology Program Committee for World Conference for Lung Cancer 2018 and currently serves as a member of the ESMO 2021 scientific committee. Rina is the principal investigator for many clinical trials in lung and breast cancers, including phase I, II and III clinical studies of immunotherapy and targeted therapies in non-small cell lung cancer and breast cancer.

Dr. Ryan is a Consultant in Division of Medical Oncology at National Cancer Centre Singapore.

Dr Samuel Ow is a Consultant Medical Oncologist in the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). He obtained his medical degree from the Yong Loo Lin School of Medicine, National University of Singapore, where he was awarded Distinction in Medicine, the Nestle Gold Medal, and placed on the Dean’s List for his academic achievements. He received the Dean’s Award for Outstanding House Officer of his entire cohort in 2007, and obtained the Masters of Medicine (Internal Medicine) and Membership of the Royal College of Physicians (UK) on an MOHH Postgraduate Exam Scholarship in 2011. He subsequently successfully completed his specialty training in Internal Medicine and Medical Oncology at NCIS where he served as Chief Registrar, and was also selected for the inaugural Singapore Chief Residency Program. Dr Samuel Ow’s clinical and research interests are in Breast Cancer and Clinical Cancer Genetics. He received a Master of Public Heath with concentration in Epidemiology and Biostatistics from the Johns Hopkins Bloomberg School of Public Health on an Academic Medicine Development Award in 2016. During his time in Baltimore, USA, he also attended sessions at the Sidney Kimmel Comprehensive Cancer Center. He is a co-investigator in several investigator-initiated and multi-national clinical trials. His research work has been published in peer-reviewed journals as well as at the American Society of Clinical Oncology Annual Meeting. He is an alumnus of the Clinical Cancer Genetics Community of Practice Intensive Course in Cancer Risk Assessment conducted by the City of Hope Comprehensive Cancer Center, and currently runs the Cancer Genetics Clinic at NCIS. He also sits on the committee for the Breast Cancer Awareness Campaign at the institutional and national level, to help drive greater awareness for breast cancer screening and prevention in the general public. Dr Samuel Ow strongly believes in the importance of training the next generation of physicians. He is an Assistant Professor on the Clinician-Educator track at the Yong Loo Lin School of Medicine, and is currently the Associate Program Director of the Medical Oncology Senior Residency Program at NCIS. He is active in medical education at the undergraduate and postgraduate level, and has been awarded for teaching excellence. On the administrative front, Dr Samuel Ow serves as Assistant Clinical Director of the Division of Medical Oncology, and is involved in improving processes to enhance clinical care in cancer patients. He is an advocate for multidisciplinary collaboration, and notably led a team from NCIS to win the Best Practice Medal (Care Redesign Category) at the National Healthcare Innovation and Productivity Medals 2019.

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on the development of novel therapies in the treatment of breast cancer.

Dr Shaheenah Dawood is a Consultant Medical Oncologist and Professor in Clinical Oncology in the United Arab Emirates. She was trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training, she was awarded multiple scholar training awards besides ASCO merit awards. Dr Shaheenah has served as an editorial fellow at the New England Journal of Medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles, and 12 book chapters. Having served as a reviewer for multiple journals including the Journal of Clinical Oncology she is currently leading the oncology clinical trials program at Mediclinic City Hospital, Dubai. She also serves as President of Excellence in Oncology Care (EIOC) annual congress held in Dubai and is Co-Chair of the Asia Pacific Breast Cancer Summit (APBCS), Asia Pacific Gastrointestinal Cancer Summit (APGCS) ,the international BRCA forum (iBRCAf) and Young Women Forum (YWF) from over a decade.

Shanu Modi, MD, is a Member of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. She received her medical degree from the University of Alberta in Edmonton, Canada where she also completed a residency in internal medicine. She followed this with subspecialty training in medical oncology at the Cross Cancer Institute and subsequently completed a 4-year fellowship in Breast Cancer Research at MSKCC. She has been a full-time faculty member on the Breast Medicine Service at MSKCC since 2005. Dr Modi has been chair and member of the Scientific Program Committee for HER2 Positive Breast Cancer from 2013-2016 and a member of the grant selection committee for the American Society of Clinical Oncology (ASCO) from 2013 to 2015. She received the Conquer Cancer Foundation Advanced Clinical Research Award in 2009 for her work in Heat Shock Protein Inhibition. And was awarded and held the Patricia and James Cayne Chair for Junior Faculty at MSKCC from 2009-2012. She also has a significant clinical research program in the development of HER2 targeted therapies and is currently the Section Head for the HER2 Breast Cancer Program on the Breast Medicine Service at MSKCC. She is also a member of the Expert Committee to establish Guidelines for Patients with Advanced HER2+ Breast Cancer, where she serves on the Breast Cancer Consensus Panel. She is also a member of the Scientific Committee for the European Society of Medical Oncology (ESMO) as part of the metastatic breast cancer track responsible for abstract selection. She is an ad hoc reviewer for the Journal of Clinical Oncology, Clinical Breast Cancer, Breast Cancer Research and Treatment, and the Journal of Surgical Oncology. She has authored or co-authored more than 50 peer-reviewed articles as well as books, book chapters, and reviews. Dr Modi holds memberships in ASCO, ESMO, the American Association for Cancer Research, ALLIANCE for Clinical Trials in Oncology, and the Translational Breast Cancer Consortium. She has been an invited speaker for national and international congresses, meetings, and symposiums.

.

Stephen Johnston is the Head of Medical Oncology, Head of the Breast Unit, Professor of Breast Cancer Medicine and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden from 2007 to 2012, and is currently Clinical Director of the Breast, Lung and AOS Clinical Business Unit at The Royal Marsden. He graduated in 1983 from Trinity College at the Cambridge University, and in 1986 from the Medical School at the University of Newcastle-upon- Tyne. He trained in general medicine at St Bartholomew's Hospital and Hammersmith Hospital in London, and subsequently in medical oncology at The Royal Marsden. He gained his PhD from The Institute of Cancer Research at the University of London, and took up his current position as Consultant Medical Oncologist in the Breast Unit at The Royal Marsden in 1997. He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II/III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors. He has published over 250 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national and international meetings. He is a member of several scientific committees and advisory boards, a prior Faculty member at the American Society for Clinical Oncology, a current member of San Antonio Breast Cancer Symposium abstract review committee, and serves as Deputy/Associate Editor for the international journals ‘Breast Cancer Research’ and ‘Clinical Breast Cancer’.

Dr. Sudeep Gupta is a Professor of Medical Oncology at Tata Memorial Hospital in Mumbai, India. Dr. Gupta obtained his MBBS degree from All India Institute of Medical Sciences (AIIMS) in New Delhi in 1992. Dr. Gupta is an outstanding researcher and has special interests in breast cancer and gynecological malignancies and early drug development. In breast cancer Dr. Gupta’s areas of research include adjuvant therapy and management approach of metastasis from breast cancer.

Dr. Sung-Bae Kim is a Professor at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. He attained his MD and PhD from Kyunghee University Medical School, completed clinical training in internal medicine at Ewha Womans University and undertook a clinical fellowship at Division of Hematology-Oncology at Asan Medical Center. He studied Experimental Transplantation and Immunology at the National Cancer Institute, Maryland, USA in 2000 as a postdoctoral fellow. Dr. Kim is affiliated with many professional associations, which include the Korean Medical Association, Korean Association for Internal Medicine, Korean Cancer Association, Korean Society of Breast Cancer, American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and the European Society for Medical Oncology (ESMO).

Dr Timothy Tay graduated from Yong Loo Lin School of Medicine, National University of Singapore and did his postgraduate residency training in Anatomical Pathology. Having completed his fellowship exams, he is a Fellow of both The Royal College of Pathologists (United Kingdom) as well as The Royal College of Pathologists of Australasia. He has a special interest in Breast, Genitourinary and Bone and Soft Tissue Pathology and currently holds a Consultant position in the Singapore General Hospital Department of Anatomical Pathology.

Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the divisional deputy director of research as well as a primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.

Dr. Valerie Heong is a medical oncologist at Tan Tock Seng Hospital. She received her medical degree from the University of Adelaide, Australia and subsequently trained in medical oncology in Melbourne, Victoria, Australia. She obtained a PhD in molecular biology from the Department of Medical Biology, University of Melbourne, Australia and subsequently moved to Singapore. During her PhD she was awarded the Ovarian Cancer Australia Postgraduate Scholarship and the Bev Gray Ovarian Cancer PhD Scholarship. She is a clinician scientist with a special interest in cancer genetics, breast and gynaecological cancer, drug development and translational research. Her research focuses on development of novel therapeutic agents and biomarker discovery in breast and ovarian cancer.

"Medical School: - M.D., Faculty of Medicine, Chulalongkorn University, Thailand, 1990 Board Certifications: - Diploma of The Thai Board of Internal Medicine, 1994 - Diploma of The Thai Board of Medical Oncology, 2004"

Professor Winnie Yeo graduated from King’s College Hospital, University of London. She underwent postgraduate training in Addenbrooke’s Hospital, Cambridge, and at King’s College, Westminster and Royal Marsden Hospitals in London before returning to Hong Kong. Professor Yeo was the Chairman of the Medical Oncology Specialty of the Hong Kong College of Physicians between 2007 and 2013. She is an Honorary Consultant in the Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong and a Co-director of the Comprehensive Cancer Trials Unit of the Department of Clinical Oncology, Faculty of Medicine, the Chinese University of Hong Kong. She serves as a member and advisor in various expert panels and committees within the University, the Hong Kong Hospital Authority and various health advisory panels. She has authored and coauthored over 230 papers including leading authorships for publications in journals including Journal of the National Cancer Institute, Journal of Clinical Oncology, Hepatology, Annals of Oncology etc. Her main research interests are management of breast, liver and gastric cancer patients as well as hepatitis B virus-related complications in cancer patients.

Wong Fuh Yong Dr Wong Fuh Yong is a senior consultant with the Division of Radiation Oncology, NCCS. He received his medical education at NUS and qualified as a Clinical Oncologist with the Royal college of Radiology, UK in 2007. He specializes in breast oncology, neuro-oncology and the use of stereotactic radiosurgery for both benign and malignant indications.

Dr Yoon-Sim Yap is a Senior Consultant in the Department of Medical Oncology at National Cancer Centre Singapore, and Visiting Consultant at KK Women’s and Children’s Hospital. She obtained her undergraduate medical degree from the University of Adelaide in Australia, and is a Fellow of the Royal Australasian College of Physicians. Dr. Yap has been practicing in Singapore since 2006, focusing mainly on breast cancer. Dr. Yap also aims to promote cancer awareness in the local population through public education, and provide holistic management of cancer patients through patient support groups and programs.

He is a initiator, protocol writer, principal investigator and co-principal investigator for various clinical trials over the years. He has written over 30 conference papers and published over 60 journals in different international peer-reviewed journals, including Lancet Oncology and Cancer Research. Dr. Lu is also the co-author in a book chapter entitled ‘Histone Deacetylase Inhibitors in Cancer Therapy’.

Yeon Hee Park, MD, professor, Breast Cancer Center, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic breast cancer, specifically in patients with central nervous system (CNS) metastases.

.